TransMedics Group, Inc. (TMDX)
| Market Cap | 2.97B -24.3% |
| Revenue (ttm) | 668.47M +25.8% |
| Net Income | 151.70M +111.7% |
| EPS | 4.01 +98.9% |
| Shares Out | 34.68M |
| PE Ratio | 21.00 |
| Forward PE | 45.19 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 68,058 |
| Open | 85.72 |
| Previous Close | 84.29 |
| Day's Range | 84.60 - 86.74 |
| 52-Week Range | 60.11 - 156.00 |
| Beta | 1.88 |
| Analysts | Buy |
| Price Target | 97.30 (+13.66%) |
| Earnings Date | Aug 4, 2026 |
About TMDX
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung tra... [Read more]
Financial Performance
In 2025, TransMedics Group's revenue was $605.49 million, an increase of 37.13% compared to the previous year's $441.54 million. Earnings were $190.29 million, an increase of 436.58%.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for TMDX stock is "Buy." The 12-month stock price target is $97.3, which is an increase of 13.66% from the latest price.
News
TransMedics to Present at Upcoming September Investor Conferences
ANDOVER, Mass., Aug. 31, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s...
Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
TransMedics Group Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of TransMedics Group, Inc. - TMDX
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced...
TransMedics Group Transcript: Canaccord Genuity's 46th Annual Growth Conference
Presented a robust, vertically integrated organ transplant platform with strong financial growth, four major expansion initiatives, and a clear path to $2–$3 billion in revenue. Strategic investments in technology, logistics, and new markets are expected to drive continued margin improvement and industry leadership.
TransMedics Group Slides: Canaccord Genuity's 46th Annual Growth Conference
TransMedics Group has posted slides in relation to its latest quarterly earnings report, which was published on August 11, 2026.
TransMedics price target lowered to $77 from $80 at UBS
UBS lowered the firm’s price target on TransMedics (TMDX) to $77 from $80 and keeps a Neutral rating on the shares.
TransMedics price target raised to $122 from $120 at Baird
Baird raised the firm’s price target on TransMedics (TMDX) to $122 from $120 and keeps an Outperform rating on the shares. The firm updated its model following mixed Q2 results…
TransMedics price target lowered to $100 from $120 at Piper Sandler
Piper Sandler analyst Matt O’Brien lowered the firm’s price target on TransMedics (TMDX) to $100 from $120 and keeps an Overweight rating on the shares. The firm notes the company…
TransMedics price target lowered to $95 from $124 at Canaccord
Canaccord lowered the firm’s price target on TransMedics (TMDX) to $95 from $124 and keeps a Buy rating on the shares. The firm said they reported a Q2 revenue beat…
TransMedics price target lowered to $65 from $80 at Stifel
Stifel lowered the firm’s price target on TransMedics (TMDX) to $65 from $80 and keeps a Hold rating on the shares.
TransMedics Group Earnings Call Transcript: Q2 2026
Record Q2 revenue of $190M was driven by strong growth in OCS case volume, clinical services, and logistics, with service revenue outpacing product revenue. Raised 2026 revenue guidance to $737–$757M, excluding PAD Aviation, and expect continued investment in growth initiatives and international expansion.
TransMedics Group Earnings release: Q2 2026
TransMedics Group released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
TransMedics Group Quarterly report: Q2 2026
TransMedics Group has published its Q2 2026 quarterly earnings report on August 4, 2026.
TransMedics Group Slides: Q2 2026
TransMedics Group has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
TransMedics reports Q2 adjusted EPS 44c, consensus 48c
Reports Q2 revenue $189.9M, consensus $183.99M. “The second quarter was a defining one for TransMedics (TMDX): record revenue, accelerating service growth, and sequential gross margin expansion, all a...
TransMedics Reports Second Quarter 2026 Financial Results
ANDOVER, Mass., Aug. 4, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-st...
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANDOVER, Mass., Aug. 3, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-st...
TransMedics price target lowered to $106 from $142 at Needham
Needham lowered the firm’s price target on TransMedics (TMDX) to $106 from $142 and keeps a Buy rating on the shares. The firm notes that its organ transplant tracker suggests…
TransMedics to Present at the Canaccord Genuity 46th Annual Growth Conference
ANDOVER, Mass., July 28, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s...
TransMedics initiated with a Neutral at UBS
UBS initiated coverage of TransMedics (TMDX) with a Neutral rating and $80 price target
TransMedics to Report Second Quarter 2026 Financial Results on August 4, 2026
ANDOVER, Mass., July 21, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s...
TransMedics price target lowered to $90 from $100 at Evercore ISI
Evercore ISI analyst Daniel Markowitz lowered the firm’s price target on TransMedics (TMDX) to $90 from $100 and keeps an Outperform rating on the shares. The firm’s Q2 preview for…
TransMedics completes strategic investment in PAD Aviation
TransMedic announced the closing of its strategic investment in PAD Aviation, a Germany-based private aviation operator. The investment in PAD Aviation is a “critical step forward” for TransMedics (TM...
TransMedics Group Announces Completion of Strategic Investment in PAD Aviation service GmbH
Strategic investment in Germany-based PAD Aviation, a premier European private aviation operator, lays the foundation for TransMedics to establish a dedicated organ transplantation air logistics netwo...